This discrepancy between the in vitro breast cancer cell line and patient survival data may be due to PKCβ-mediating physiological processes within the breast tumor microenvironment (TME), which could cause the evaluation of PKCβ expression in whole tumor tissue, which contains both tumor and stroma, to be misleading. Here, PRKCB is linked to breast carcinoma.